H.C. Wainwright downgraded Akero Therapeutics (AKRO) to Neutral from Buy with a price target of $54, down from $72, after the company entered into a merger agreement to be acquired by Novo Nordisk (NVO) at a price of $54.00 per share in cash. The firm does not expect an additional bidder to emerge.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO: